Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants

Immunogenicity Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01763268
• Other study ID #: Trivivac2012
• Status: Recruiting
• Phase: Phase 2/Phase 3
• First received: January 3, 2013
• Last updated: January 5, 2013
• Start date: September 2012
• Est. completion date: August 2015

Study information

• Verified date: January 2013
• Source: Queen Sirikit National Institute of Child Health
• Contact: Warunee P Vandepitte, MD, PhD
• Phone: 66855158299
• Email: waruneep[@]gmail.com
• Is FDA regulated: No
• Health authority: Thailand: Queen Sirikit National Institute of Child Health
• Study type: Interventional

Clinical Trial Summary

Open-label, single-arm trial, Primary Objectives included:

1. To assess the immunogenicity of TrivivacTM administered in healthy infants aged between 9-14 months.

2. To assess the safety (reactogenicity) of TrivivacTM administered in healthy infants aged between 9-14 months.

The study will be done on healthy infants, 9-14 months of age. After enrolment, the infants will be given one dose of primary vaccination MMR (TrivivacTM),SEVAPHARMA BiogenetechLtd. study vaccines will be administered subcutaneously into the anterolateral aspect of right thigh.outer aspect of the upper arm. Subjects will be followed at approximately 6 weeks after primary vaccination to evaluate response to primary immunization of this vaccine. Blood sample will be collected from subjects at visit 1 (prior to immunization) and visit 2 (6 weeksone month after completion of this first dose of immunization). The serum samples will be analysed for Anti-measles, Anti-mumps and Anti-rubella antibodies. Proportion of subjects achieving seroprotection and geometric mean titers of antibody against measles, mumps, rubella at 6 weeks after one dose vaccination of MMR vaccine at aged 9-14 months will be evaluated. Adverse reactions will be observed on each vaccination day (up to 30 minutes) and for 4 days (Day 0-3) after each dose. Adverse reactions will also be monitored for 30 days following each vaccination. Serious adverse events will be monitored for the entire study duration.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: August 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 9 Months to 14 Months

Eligibility

Inclusion Criteria:

1. Infants aged 9-14 months whose parents/LAR give written informed consent prior to the study entry.

2. Infants with good health as determined by: Medical history, Physical examination, Clinical judgment of the investigator

3. Infants who are not seroprotected against MMR virus by virtue of previous immunization and/or proven prior infection.

Exclusion Criteria:

1. Children whom parents or LAR are unwilling or unable to give written informed consent to participate in the study.

2. Any evidence of acute illness or infection within past 14 days.

3. Planned or elective surgery during the course of the study.

4. Infants born before the 37th week of gestation.

5. Birth weight less than 2.5 kg.

6. Infants with a known or suspected impairment of the immune function, or those receiving immunosuppressive therapy, or having received immunosuppressive therapy within 1 month prior to study entry (including systemic corticosteroids) or those who have received a parenteral immunoglobulin preparation.

7. Any history suggestive of thrombocytopenia or a bleeding disorder.

8. Infants who have received any blood products (within 3 months prior to study entry), cytotoxic agents or radiotherapy.

9. Infants with history of anaphylaxis, or any serious vaccine reaction, or allergy to any vaccine component (e.g. neomycin, gelatine, canine proteins).

10. Infants with any serious chronic disease such as cardiac, autoimmune disease or insulin dependent diabetes or with any condition that in the opinion of the investigator might interfere with the evaluation of the study objectives.

11. Infants whose families are planning to leave the area of the study site before the end of the study period.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Immunogenicity
• Reactogenicity

Intervention

Biological:
• Trivivac vaccine
Trivalent MMR vaccine

Locations

Country	Name	City	State
Thailand	Queen Sirikit National Institute of Child Health	Bangkok

Sponsors (1)

Lead Sponsor	Collaborator
Queen Sirikit National Institute of Child Health

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immunogenicity as measured by the proportion of subjects achieving seroprotection against measles, mumps and rubella	Immunogenicity of Trivivac vaccine is determined by proportion of subjects achieving seroprotection against measles, mumps and rubella at 6 weeks (42 days) after application of first dose of vaccine MMR. The amount of specific antibodies against measles, mumps and rubella will be evaluated in sera collected approximately 42+ 7 days following primary vaccination with the Trivivac vaccine.; Seroconversion and GMT against measles, mumps, and rubella will be defined by Enzyme immunoassay for the qualitative detection and quantitative determination of specific IgG antibodies against measles, mumps and rubella virus in human serum (Enzygnost® Anti-Measles Virus/IgG, Anti-Mumps Virus/IgG and Anti-Rubella Virus/IgG; SIEMENS).	6 weeks after vaccination	No
Secondary	Reactogenicity as measured by the prevalence of local and systemic adverese reaction	Occurrence, intensity and relationship to vaccination of early expected and unexpected local and systemic adverse drug reactions reported during the 4-day (Day 0-3) follow-up period after vaccination.	Day0 to day3 after vaccination	Yes